Filing Flows › Health Care › Viemed Healthcare (VMD)
Viemed Healthcare (VMD) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 4, 2026 · Viemed Healthcare (VMD) Q3 2026 earnings results →
Q3 2026 Revenue up 12% year over year to $80.7M · 6¢ of every $1 of revenue kept as net profit · operating margin 8.6%
Viemed Healthcare made $80.7M in Q3 2026 (+12% Y/Y). Operating margin 8.6%, net earnings $4.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 4, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $80.7M in Q3 2026, up 12% year over year and up 3% from the previous quarter.
Gross margin was 57.3%, down 0.2 points from Q3 2025. Operating profit was $7.0M, a 8.6% margin (up 0.8 points year over year). Of the extra revenue versus Q3 2025, 15% reached operating profit, above the 8% margin then. Operating expenses grew 10% against revenue growth of 12%. The fastest-growing cost line was SG&A (+11%). Net earnings were $4.6M, up 32% year over year. The effective tax rate was 30.2%.
Operating cash flow was $11.5M (down 37% year over year), 242% of net income including minority interests. Non-cash charges added back $7.7M of depreciation and amortization and $2.5M of share-based compensation. Working capital and other items used $3.4M. After purchase of property and equipment, net ($7.5M), free cash flow as the company reports it was $4.0M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 4, 2026 | $80.7M | +12% | 8.6% | $4.6M | $11.5M |
| Q2 2026 | 10-Q | Aug 3, 2026 | $78.1M | +24% | 5.7% | $2.8M | $15.9M |
| Q1 2026 | 10-Q | May 5, 2026 | $75.4M | +28% | 5.7% | $2.6M | $8.1M |
| Q4 2025 | 10-K | Mar 4, 2026 | $76.2M | +26% | 11.0% | $5.6M | $18.4M |
| Q3 2025 | 10-Q | Nov 5, 2025 | $71.9M | +24% | 7.8% | $3.5M | $18.4M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $63.1M | +15% | 8.1% | $3.2M | $12.3M |
| Q1 2025 | 10-Q | May 7, 2025 | $59.1M | +17% | 6.5% | $2.6M | $2.9M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- Medicare & Medicaid — 40% of its revenue · Stated in 10-K (sentence) · source
About Viemed Healthcare
Viemed Healthcare, Inc. (the "Company" or "Viemed"), through its subsidiaries, is a provider of home medical equipment ("HME") and post-acute healthcare services in the United States, with a focus on respiratory, chronic care, and women’s health products and services. The Company’s primary service offerings are focused on effective in-home treatment with clinical practitioners providing therapy and counseling to patients in their homes using cutting edge technology. Viemed’s primary objective is to drive growth by increasing the number of patients served and the level of care provided through its technology-enabled, home-based clinical care and chronic disease management model. Viemed's care programs are designed specifically to treat patients in the home for less total cost and with a superior quality of care.
In its own words, from its 10-K, filed Mar 4, 2026.
Viemed Healthcare against its Services-Misc Health & Allied Services, NEC peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +12% against the peers' median +5%. Operating margin: 8.6% against the peers' median 8.9%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| VMD Viemed Healthcare | Q3 2026 | $80.7M | +12% | 8.6% |
| DVA Davita | Q3 2026 | $3.6B | +5% | 14.0% |
| AGL agilon health | Q3 2026 | $1.5B | +6% | 1.6% |
| PGNY Progyny | Q3 2026 | $341M | +9% | 10.3% |
| SHC Sotera Health | Q3 2026 | $325M | +4% | 25.8% |
| PARK Park Dental Partners | Q2 2026 | $66.2M | +5% | 1.9% |
| CCEL Cryo Cell International | Q3 FY26 | $7.8M | 0% | 28.0% |
| MRAI Marpai | Q2 2026 | $4.2M | -10% | -82.4% |
| PFHO Pacific Health Care Organization | Q3 2026 | $1.5M | -5% | 8.9% |
Source: Viemed Healthcare 10-Q on SEC EDGAR · CIK 1729149 · Services-Misc Health & Allied Services, NEC
Guidance and outlook
13F: who owns VMD and who is buying
More on VMD
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results